Board of Directors

As of June 30, 2026, the Board of Directors consists of seven members, including five Independent Directors and two Internal Directors. As a general rule, the Board holds ten regular meetings each year.
Independent Directors with extensive management experience and a global perspective actively question and advise Executive Officers from a wide range of viewpoints, resulting in rigorous and constructive discussions. The Company also strives to keep directors informed of significant legal and regulatory developments and corporate governance trends through lectures and briefings conducted by external experts. In FY2025, the Board consisted of seven directors, two of whom were women. The Board met ten times during the year. One director attended 90% of the meetings, while all other directors achieved a 100% attendance rate. Written resolutions of the Board of Directors conducted pursuant to Article 370 of the Companies Act during FY2025 are not included in the attendance calculations above.

In accordance with the Board of Directors Regulations, the Board deliberates and approves matters required by law, as well as business portfolio reviews, quarterly budgets and financial results, risk management matters, M&A transactions, executive management structures, and Group policies relating to sustainability and compliance. The Board also receives reports on operational activities and medium- to long-term business plans from each business division.

The Company conducts an annual evaluation of the operation and effectiveness of the Board of Directors and its committees through a questionnaire survey, and the results are analyzed by the Board.

A summary of the FY2025 third-party evaluation is as follows:

■The Board is fulfilling its responsibilities with an appropriate size and composition.

■While there remains room for improvement regarding the timing of materials distribution and meeting frequency, Board operations are generally effective, and discussions on medium- to long-term strategy have become increasingly substantive.

■The Nomination, Compensation, Audit, and Healthcare Compliance Committees all engage in thorough discussions with appropriate membership and composition.

■Issues identified in the previous year's evaluation, namely:
･further discussion of key management issues,
･deeper discussion of CEO succession planning, and
･enhanced discussion of sustainability-related risks, have generally been addressed through more robust deliberations. In particular, with respect to management issues, timely and appropriate updates from management have enabled deeper Board discussions regarding medium- to long-term strategic direction, including business portfolio transformation.

■Going forward, the Board recognizes the need to continue discussions regarding the Group's organizational structure, medium- to long-term investments, and risk management.

To further improve the quality of discussions, the Company will continue enhancing Board operations, strengthening communication among Independent Directors and between Independent Directors and Executive Officers, and deepening succession planning discussions within the Nomination Committee, with the aim of further improving Board effectiveness.

Board Member Profiles

Independent Directors

Internal directors

The average tenure of the Directors is 4.57 years.
Please see the website for further details.